JBIO Straddle Strategy

JBIO (Jade Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

JBIO (Jade Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $817.9M, a beta of 1.52 versus the broader market, a 52-week range of 6.565-28, average daily share volume of 548K, a public-listing history dating back to 2025, approximately 50 full-time employees. These structural characteristics shape how JBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.52 indicates JBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. JBIO pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a straddle on JBIO?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current JBIO snapshot

As of May 15, 2026, spot at $23.54, ATM IV 152.80%, IV rank 24.68%, expected move 43.81%. The straddle on JBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on JBIO specifically: JBIO IV at 152.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a JBIO straddle, with a market-implied 1-standard-deviation move of approximately 43.81% (roughly $10.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on JBIO should anchor to the underlying notional of $23.54 per share and to the trader's directional view on JBIO stock.

JBIO straddle setup

The JBIO straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JBIO near $23.54, the first option leg uses a $23.54 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JBIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JBIO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$23.54N/A
Buy 1Put$23.54N/A

JBIO straddle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

JBIO straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on JBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on JBIO

Straddles on JBIO are pure-volatility plays that profit from large moves in either direction; traders typically buy JBIO straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

JBIO thesis for this straddle

The market-implied 1-standard-deviation range for JBIO extends from approximately $13.23 on the downside to $33.85 on the upside. A JBIO long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current JBIO IV rank near 24.68% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JBIO at 152.80%. As a Healthcare name, JBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JBIO-specific events.

JBIO straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JBIO alongside the broader basket even when JBIO-specific fundamentals are unchanged. Always rebuild the position from current JBIO chain quotes before placing a trade.

Frequently asked questions

What is a straddle on JBIO?
A straddle on JBIO is the straddle strategy applied to JBIO (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With JBIO stock trading near $23.54, the strikes shown on this page are snapped to the nearest listed JBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are JBIO straddle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the JBIO straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 152.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a JBIO straddle?
The breakeven for the JBIO straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JBIO market-implied 1-standard-deviation expected move is approximately 43.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on JBIO?
Straddles on JBIO are pure-volatility plays that profit from large moves in either direction; traders typically buy JBIO straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current JBIO implied volatility affect this straddle?
JBIO ATM IV is at 152.80% with IV rank near 24.68%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related JBIO analysis